Research & Development
Noze nabs $1M grant from Bill & Melinda Gates Foundation to develop breath testing platform
The aim is to develop a platform that enables rapid screening and diagnostic testing for infectious diseases such as malaria and tuberculosis that impact millions of people, particularly in developing countries, Noze said.
March 14, 2023
Roche, CDC expand partnership on HIV and TB support for healthcare systems in critical regions
The public-private partnership, named Lab Networks for Health, aims to improve HIV and TB detection, prevention, and treatment in countries that have been hit hardest by the two diseases.
February 28, 2023
Qiagen obtains CE Mark for tuberculosis blood test
Qiagen’s Ipsogen JAK2 RGQ PCR kit and NeuMoDx systems and reagents have already received CE Marks under the new IVDR requirements; the firm has pledged to transition all of its products to meet the new EU IVDR regulations.
February 15, 2023
Bill & Melinda Gates Foundation awards $14.2M in grants to LumiraDx to develop TB testing system
With support from the foundation, LumiraDx is developing a portable system to provide testing at a lower cost and incorporate a tongue swab that makes it easier for a higher percentage of patients to be tested.
December 14, 2022
Qiagen touts expanded uses for SARS-CoV-2, tuberculosis tests
QIAcuity is the company's digital PCR platform that uses nanoplates to process samples in two hours. Qiagen recently entered into two new collaborations that aim to extend the platform's ecosystem.
January 6, 2022
Qiagen launches new tuberculosis test
The QIAreach QuantiFERON-TB test is a portable device that enables the ultrasensitive digital detection of TB infection and increases access to reliable interferon gamma release assay (IGRA) testing.
October 19, 2021
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Quest Diagnostics offers suite of services for transplant patients and living donors
Rapid nirmatrelvir treatment in study reduced long-COVID risk
How pathologists act as 'firefighters' during COVID-19
Especially in the early stages of the pandemic, there were numerous unknowns about how to proceed with autopsies because COVID-19 was an unknown disease. What type of infectious disease was it? Was it like tuberculosis, HIV, hepatitis C, or mad cow disease?
October 3, 2021
PerkinElmer to buy Oxford Immunotec Global
The acquisition will help PerkinElmer expand its infectious disease testing portfolio to include tuberculosis detection, giving it access to Oxford Immunotec's T-cell immunology technology for testing latent tuberculosis, it said.
January 6, 2021
Qiagen debuts solution for SARS-CoV-2 T-cell research
QuantiFeron SARS-CoV-2 ROU is a modular system based on the platform Qiagen developed for its QuantiFeron-TB Gold Plus test for latent tuberculosis.
December 6, 2020
Cepheid's tuberculosis test detects drug resistance
The company's Xpert Mycobacterium tuberculosis/extensively drug-resistant (MTB/XDR) test identifies tuberculosis that is resistant to first- and second-line drugs, particularly the disease's most complicated form -- XDR-TB -- the company said.
July 15, 2020
Qiagen TB blood test gets thumbs up in Nigeria
Nigeria is the first high-burden country to exclusively embrace interferon gamma release assays (IGRAs) for latent TB screening of at-risk individuals in tuberculosis control programs, Qiagen noted. The national guidelines are based on World Health Organization (WHO) recommendations for screening, and including IGRA tests will help avoid progression to active TB, Dr. Adebola Lawanson, national coordinator of the TB program at the Nigeria Federal Ministry of Health, said in a statement from the company.
February 20, 2020
Which eligible gene signatures make the grade for TB blood tests?
The review evaluated whole blood mRNA signatures that have been proposed for identifying the onset of TB. The authors used a patient-level pooled dataset of four studies that included 1,126 samples from 905 patients, with 183 samples from 127 cases of incipient tuberculosis, which is defined as the asymptomatic phase of disease. The dataset included cases from African countries -- South Africa, Ethiopia, and Gambia -- and the U.K.
January 19, 2020
Page 1 of 2